Plasma

Plasma pTau181 in combination with ApoE4 assays registered a high degree of accuracy in ruling out patients with a low probability of amyloid pathology in the early stages of Alzheimer’s disease, according to a poster presentation at CTAD.

A plasma phosphorylated-tau217 assay demonstrated a high degree of accuracy in identifying biomarkers consistent with Alzheimer’s disease-related pathology, according to research from JAMA Neurology.

Platelet-rich plasma therapy may be more effective than minoxidil in treating androgenetic alopecia, according to a study.

Patients with hidradenitis suppurativa saw improvement with fostamatinib treatment, showing that targeting B cells and plasma cells could be an upcoming strategy in treating the disease, according to a study.

Investigators proposed a way to classify subgroups of patients with AKI using plasma and urine biomarkers, according to research published in the American Journal of Kidney Diseases.

Adding once-daily opicapone 50 mg to carbidopa/levodopa therapy helped achieve and maintain plasma concentrations of levodopa in patients with Parkinson’s disease, according to research in Clinical Neuropharmacology.

Published results showed plasma D-dimer was noninferior to serum C-reactive protein and erythrocyte sedimentation rate in the diagnosis of periprosthetic joint infection.

SAN ANTONIO — Elevated cognitive impairment appeared linked to weak asthma control among older adults, according to an abstract presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

Researchers observed immunoglobulin A autoantibodies that target lung surfactant proteins B and C in patients with severe COVID-19, according to study results published in American Journal of Respiratory Medicine and Critical Care.

The plasma biomarker P-tau217 predicted cognitive decline in patients with preclinical Alzheimer’s disease and may complement cerebrospinal fluid and positron emission tomography as a patient-screening tool in clinical trials.